* For FACTBOX on vaccines and treatments, click:
(Updates with European Union deal, AstraZeneca's 3 billion dose
target)
Aug 14 (Reuters) - The European Union has agreed to buy at
least 300 million doses of AstraZeneca's potential COVID-19
vaccine, with an option to buy another 100 million.
Drugmakers are racing to combat the pandemic that has killed
about 760,000 people and infected nearly 21 million.
There are no approved vaccines for COVID-19, but AstraZeneca's
shot is widely seen as one of the leading candidates.
The company has been granted protection from future product
liability claims related to the vaccine by most of the countries
with which it has so far struck supply agreements, a senior
executive told Reuters.
Below are the main details of AstraZeneca's coronavirus vaccine
hopeful and its supply and production deals.
TYPE
* The shot, called AZD1222 or ChAdOx1 nCoV-19, is a recombinant
viral
vector vaccine developed by Oxford University.
* It was licensed to AstraZeneca in April.
* The vaccine candidate uses a weakened version of a chimpanzee
common-cold virus that encodes instructions for making proteins
from the novel coronavirus to build immunity.
PROTECTION DURATION
* The shot is likely to provide protection for about a year,
and the
company is leaning towards a two-dose strategy for the potential
vaccine.
EXPECTED COST
* AstraZeneca says it will be able to manufacture the vaccine
at a
few dollars per dose.
* Pricing in Latin America, while still not final, is not
expected to
exceed $4 per dose, said AstraZeneca's Mexico head.
* India's Serum Institute said it will price the shot at $3 per
dose
for the country and other emerging economies.
* According to Italy's health ministry, an AZD1222 shot would
cost
about 2.5 euros ($2.8) per dose in Europe.
* AstraZeneca has said it does not expect to profit from the
vaccine
candidate during the pandemic.
* Costs in other regions have not been disclosed.
TRIALS
* AstraZeneca's CEO said good data has come in so far on the
shot,
after early-stage clinical trials showed it was safe and produced
an immune response.
* Late-stage trials are currently underway in Britain, Brazil
and
South Africa, and are due to start in the United States in the
third quarter.
* Talks are ongoing with Mexico, and reports have said the
Indian
regulator has also given a nod for mid-to-late-stage trials.
TIMELINE
* The vaccine could be rolled out by year-end, but there is no
certainty of that, its lead developer said in July.
* Data from late-stage studies is expected by August to
September.
* Delivery of the first doses is expected between September and
October.
* Experts predict a safe and effective vaccine could take 12-18
months to develop.
TARGET DOSES
* Recent supply deals take target doses to 3 billion,
AstraZeneca
said.
TIE-UPS
* With U.S. backing, AstraZeneca has tied up with IQVIA
to
speed up trials. Even before conclusive evidence of the vaccine's
success or failure, AstraZeneca has signed other deals to produce
and supply the shot.
MANUFACTURING DEALS
(Most recent first)
FIRM BASED IN DEAL VALUE FOR FURTHER
Foundation Mexico Unknown Latin [nL1N2FF
of Mexican American 01U]
billionaire supply with
Carlos Slim Argentina,
excluding
Brazil
mAbxience of Argentin Unknown Initially [nL1N2FF
the INSUD a producing 150 01U]
Group million doses
for Latin
America,
excluding
Brazil
Kangtai Bio China Unknown Annual [nL4N2F8
production 2GT]
capacity of
at least 100
million doses
this year,
and at least
200 million
doses by the
end of next
year
Emergent U.S. $174 Undisclosed [nL3N2EY
BioSolutions million doses 2LF]
SK South Unknown Undiluted [nL3N2ES
Bioscience Korea solutions of 288]
the vaccine
R-Pharm Russia Unknown Unknown doses [nL5N2EO
2S4]
Daiichi Japan Unknown Unknown doses [nL4N2E3
Sankyo 19J]
Fundação Brazil $127 About 30 [nL1N2E4
Osvaldo Cruz million million doses 03I]
(Fiocruz)
Symbiosis Scotland Undisclosed Clinical [nL4N2E1
Pharmaceutic trial supply 2U2]
al
Cobra U.S. Undisclosed One million [nL8N2DT
Biosciences doses per 1YB]
month
Catalent U.S. Undisclosed Vial filling [nL4N2DS
and packaging 2XW]
Emergent U.S. $87 million 300 million [nL4N2DO
BioSolutions doses 2U1]
Serum India Undisclosed One billion [nL4N2DH
Institute of doses for low 3LY]
India and
middle-income
countries,
with 400
million
before end of
2020
Oxford UK Undisclosed Undisclosed [nL4N2DL
Biomedica doses 1B3]
SUPPLY DEALS
(Most recent first)
REGION/FIRM DOSES FUNDING DELIVERIES FURTHER
European Union 300 million, Undisclose By end of [nL8N2FG
with option d 2020 2XV]
of
additional
100 million
Latin America, Initially Estimated First half of [nL1N2FF
excluding produce 150 at $600 2021 01U]
Brazil million million
doses, and for the
eventually first 150
make at million
least 400 doses
million
Japan 120 million Undisclose 30 million [nL4N2F9
doses d doses by 2XN]
March 2021
China Annual Unknown By end of [nL4N2F8
production 2020 2GT]
capacity of
at least 100
million
doses this
year
South Korea Unknown Unknown Unknown [nL3N2ES
288]
Russia Unknown Unknown Unknown [nL5N2EO
2S4]
Israel Unknown Unknown Unknown [nL5N2ER
4TW]
Brazil Initially $356 Unknown [nL1N2F8
receive 100 million 2TN]
million
doses
France, 300 million, 750 By end of [nL8N2DQ
Germany, Italy with option million 2020 0GG]
and the of euros for
Netherlands additional 300
under Inclusive 100 million million
Vaccines doses
Alliance (IVA)
Italy (part of 75 million 185 By end of [nL8N2DS
IVA) million 2020 2XO]
euros
Serum Institute One billion, Unknown 400 million [nL4N2DH
of India unspecified before the 3LY]
number of end of 2020
doses will
go to India
Epidemic 300 million $750 Some before [nFWN2DH
response group million, end of 2020 0DK]
CEPI and with $383
Vaccine from CEPI
alliance GAVI
United States 300 million $1.2 By Oct [nL4N2D3
billion 1M3]
United Kingdom 100 million Unknown By Sept/Oct [nRSU597
2Na]
AstraZeneca is also in talks with Spain.
Sources: Reuters reporting, press releases
($1 = 0.8850 euros)
($1 = 0.8156 pounds)
(Reporting by Pushkala Aripaka in Bengaluru; Additional reporting
by Tanishaa Nadkar; Editing by Jason Neely, Nick Macfie, Sherry
Jacob-Phillips and Jan Harvey)
